Valganciclovir

• CAT Number: I002292
• CAS Number: 175865-60-8
• Molecular Formula: C14H22N6O5
• Molecular Weight: 354.36
• Purity: ≥95%
• Synonyms: Cymeval; Valganciclovir [INN:BAN]; L-Valine, ester with ganciclovir
• Target: CMV
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IUPAC Name: [2-[(2-amino-6-oxo-1H-purin-9-yl)methoxy]-3-hydroxypropyl] (2S)-2-amino-3-methylbutanoate
• InChI: InChI=1S/C14H22N6O5/c1-7(2)9(15)13(23)24-4-8(3-21)25-6-20-5-17-10-11(20)18-14(16)19-12(10)22/h5,7-9,21H,3-4,6,15H2,1-2H3,(H3,16,18,19,22)/t8?,9-/m0/s1
• InChIKey: WPVFJKSGQUFQAP-GKAPJAKFSA-N
• SMILES: CC(C)C(C(=O)OCC(CO)OCN1C=NC2=C1N=C(NC2=O)N)N

Valganciclovir(CAT: I002292) is an antiviral medication and a prodrug of ganciclovir. It is commonly used for the treatment of cytomegalovirus (CMV) infections, particularly in immunocompromised individuals, such as those with HIV/AIDS or those who have undergone organ transplantation. Once inside the body, valganciclovir is converted into ganciclovir, which works by inhibiting the replication of CMV DNA. By blocking viral replication, valganciclovir helps to control and reduce the severity of CMV infections.

Reference

[1]. Sugawara M, et al. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J Pharm Sci. 2000 Jun;89(6):781-9.
[2]. Chawla JS, et al. Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature. Transpl Infect Dis. 2012 Jun;14(3):259-67.
[3]. O/'Brien S, et al. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood. 2008 Feb 15;111(4):1816-9.